[Prevalence and diversity of management of prostate cancer patients classified as low risk using D'Amico group or Cancer of the Prostate Risk Assessment (CAPRA) score: A French multicenter study].

CONCLUSIONS: In absence of strong progression predictor, the management of low risk PCa remains based on center habits and local therapeutic platforms. New predictive markers, such as multiparametric MRI or molecular tests, are needed to guide rational management of low risk PCa. LEVEL OF EVIDENCE: 4. PMID: 28258910 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/28258910?dopt=Abstract

Source: Progres en Urologie - March 6, 2017 Category: Urology & Nephrology Tags: Prog Urol Source Type: research